Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 4/20 | 0.34 |
| ▸ | WNT3A | P56704 | 4/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | QPCT | Q16769 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | PIR | O00625 | 1/20 | 0.32 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4143015 | 0.85 | CTNNB1 (0.37) | CTNNB1WNT3AHTR1DHTR2COGA | |
| SCHEMBL4131659 | 0.79 | NPC1 (0.38) | UHRF1 | |
| SCHEMBL23087988 | 0.78 | CTNNB1 (0.34) | CTNNB1WNT3AHTR1DHTR2COGA | |
| SCHEMBL4153041 | 0.78 | CLK1 (0.35) | CTNNB1WNT3AHTR1DHTR2COGA | |
| SCHEMBL18237921 | 0.77 | OGA (0.37) | CTNNB1WNT3AHTR1DHTR2COGA | |
| SCHEMBL13952606 | 0.77 | CTNNB1 (0.35) | CTNNB1WNT3AHTR1DHTR2COGA | |
| SCHEMBL24156960 | 0.75 | OGA (0.40) | CTNNB1WNT3AOGANOTUMALK | |
| SCHEMBL102651 | 0.74 | UHRF1 (0.37) | UHRF1CHRNA7 | |
| SCHEMBL23088151 | 0.74 | CTNNB1 (0.35) | CTNNB1WNT3AHTR1DHTR2COGA | |
| SCHEMBL10313886 | 0.74 | CTNNB1 (0.37) | CTNNB1WNT3AHTR1DHTR2COGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411419-A1 | SMALL MOLECULE MODULATORS OF MHC-I | RETROVIROX, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20210078999-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | CHARLES RIVER LABORATORIES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022793-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411419-A1 | SMALL MOLECULE MODULATORS OF MHC-I | CD74, HLA-DRB1, MICA | CTNNB1 3045/4885WNT3A 1815/4885HTR1D 2147/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | CTNNB1 4078/4885WNT3A 4472/4885HTR1D 4441/4885 |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | CTNNB1 3780/4885WNT3A 2759/4885HTR1D 3353/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | CTNNB1 3751/4885WNT3A 2689/4885HTR1D 3338/4885 |
| US-20210078999-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | KLKB1, KLK1, KLK5 | CTNNB1 4535/4885WNT3A 3965/4885HTR1D 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.